TITLE

PRoFESS Trial Shows No Stroke Benefit

PUB. DATE
October 2008
SOURCE
Travel Medicine Advisor;Oct2008 Supplement, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article cites studies and trials conducted on subjects administered with certain drugs to prevent recurrence of strokes. In the first arm of the PRoFESS trials, authors of the study observed that therapy of 80 mg telmisartan on patients who had suffered ischemic strokes did not lower recurrence of ischemic strokes, diabetes, and major cardiovascular events. In the second part of the trials, the incidence of recurrent stroke in patients who took aspirin and dipyridamole was not significantly different from those who took clopidogrel.
ACCESSION #
34907289

 

Related Articles

  • Preventing TIAs: Ticlopidine is more effective than aspirin.  // Geriatrics;Mar94, Vol. 49 Issue 3, p64 

    Presents an abstract on the article `Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events,' by A.Bellevance. Comparison between ticlopidine and aspirin recipients; Reduction of risk of reversible ischemic events.

  • M'S SCIENCE INITIATES EUROPEAN PHASE 2 STROKE RECOVERY.  // Worldwide Biotech;Mar2008, Vol. 20 Issue 3, p5 

    This article deals with the clinical trial initiated by M's Science Corporation (MSC), a clinical stage discovery and development company, in Europe with its lead product SA4503 for the treatment of stroke. The target number of patients for this study is 60. The trial aims to evaluate the safety...

  • PRoFESS Trial Shows No Stroke Benefit.  // Infectious Disease Alert;Oct2008 Primary Care, Vol. 13 Issue 10, p2 

    The article reports that PRoFESS trial showed no evidence that the two treatments for preventing recurrent strokes were superior to the other. The first strategy compared the angiotensin-receptor blocker telmisartan to placebo in patients with ischemic stroke, while the second strategy compared...

  • t-PA FOR TREATING ACUTE ISCHEMIC STROKE. Shaughnessy, Allen S.; Scow, Dean Thomas // Journal of Family Practice;May96, Vol. 42 Issue 5, p458 

    The article discusses research being done on the use of tissue plasminogen activator (t-PA) for treating acute ischemic stroke. It references a study by the National Institute of Neurological Disorders and Stroke t-PA Stroke Study Group published in a 1995 issue of "The New England Journal of...

  • Abciximab: unfavourable benefit-risk profile in ischaemic stroke.  // Reactions Weekly;2/9/2008, Issue 1188, p4 

    The article discusses research on the effectiveness of abciximab in patients with acute ischemic stroke. It references a study by H. P. Adams Jr. and colleagues published in the January 2008 issue of "Stroke." The researchers examined the effectiveness and tolerability of early administration of...

  • Efficacy and Safety of a Metabolic Modulator Drug in Chronic Stable Angina: Review of Evidence from Clinical Trials. Chaitman, Bernard R. // Journal of Cardiovascular Pharmacology & Therapeutics;Sep2004 Supplement, Vol. 9 Issue 1S, pS47 

    The article presents research which dealt with the efficacy and safety of the metabolic modulator drug Ranolazine in treating chronic stable angina. The efficacy and safety of the drug was assessed in both the Monotherapy Assessment of Ranolazine In Stable Angina and Combination Assessment of...

  • Fosfomycin: an old, new friend? Popovic, M.; Steinort, D.; Pillai, S.; Joukhadar, C. // European Journal of Clinical Microbiology & Infectious Diseases;Feb2010, Vol. 29 Issue 2, p127 

    Fosfomycin (FOM) is an antibiotic which has varying application indications across the globe. European, Japanese, South African and Brazilian usage practices are much broader, involving multiple formulations of FOM than the currently limited application of FOM in the United States, where...

  • Refractory Epilepsy: One Size Does Not Fit All. French, Jacqueline A. // Epilepsy Currents;Nov2006, Vol. 6 Issue 6, p177 

    A unifying definition of refractory epilepsy has been hotly debated but, to date, has not been agreed upon. Evidence from clinical trials indicates that some patients actually are not refractory, as many will partially respond to add-on treatment or will worsen when antiepileptic drugs (AEDs)...

  • Another Role for Aspirin?  // Kentucky Nurse;Oct-Dec2007, Vol. 55 Issue 4, p4 

    The article discusses research on the use of aspirin in patients with previous colorectal cancer. It references a study by a research group including R. S. Sandler published in an issue of "The New England Journal of Medicine." According to the randomized, double-blind, clinical trial, a lesser...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics